Skip Navigation LinksHome > July 2013 - Volume 32 - Issue 7 > Topical Ranibizumab as a Treatment of Corneal Neovasculariza...
Cornea:
doi: 10.1097/ICO.0b013e3182775f8d
Clinical Science

Topical Ranibizumab as a Treatment of Corneal Neovascularization

Ferrari, Giulio MD*; Dastjerdi, Mohammad H. MD; Okanobo, Andre MD; Cheng, Sheng-Fu MD; Amparo, Francisco MD; Nallasamy, Nambi; Dana, Reza MD, MSc, MPH

Supplemental Author Material
Collapse Box

Abstract

Purpose:

To examine the effect of topical ranibizumab on clinically stable corneal neovascularization (NV).

Methods:

This was a prospective, open-label, monocentric, uncontrolled noncomparative study. Ten eyes of 9 patients with corneal NV received topical ranibizumab (1%) 4 times a day for 3 weeks with a follow-up period of 16 weeks. The main corneal NV outcome measures were: neovascular area, the area occupied by the corneal neovessels; vessel caliber (VC), the mean diameter of the corneal neovessels; and invasion area (IA), the fraction of the total cornea area covered by the vessels. This study was conducted at the Massachusetts Eye and Ear Infirmary, Boston, MA.

Results:

Statistically significant decreases in neovascular area (55.3%, P < 0.001), which lasted through 16 weeks, and VC (59%, P < 0.001), which continued to improve up to week 16, were observed after treatment. No significant decrease was observed in IA (12.3%, P = 0.49). There was no statistically significant change in visual acuity or intraocular pressure. No adverse events ascribed to the treatment were noted.

Conclusions:

Topical application of ranibizumab is effective in reducing the severity of corneal NV in the context of established corneal NV, mostly through decrease in VC rather than IA.

Copyright © 2013 by Lippincott Williams & Wilkins

Login

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.